|
Identified risk factors
|
5 (71.4)
|
19 (82.6)
|
0.6
|
|
Hemolytic anemia
| | | |
|
Hereditary spherocytosis
|
1 (14.3)
|
1 (4.3)
|
0.4
|
|
Major thalassemia
|
0 (0)
|
1 (4.3)
|
1.0
|
|
G6PD deficiency
|
2 (28.6)
|
7 (30.4)
|
1.0
|
|
Dehydration
|
1 (14.3)
|
5 (21.7)
|
1.0
|
|
Therapy with ceftriaxone
|
2 (28.6)
|
4 (17.4)
|
0.6
|
|
Family history of gallstones
|
1 (14.3)
|
4 (17.4)
|
1.0
|
|
Hypertriglyceridemia
|
1 (14.3)
|
3 (16.7)
|
1.0
|
|
Cholestasis
|
0(0)
|
2 (8.7)
|
1.0
|
|
Prematurity
|
0 (0)
|
2 (8.7)
|
1.0
|
|
Cystic fibrosis
|
0 (0)
|
1(4.3)
|
1.0
|
|
Hemoglobin (g/dl) in mean ± SD
|
11.5 ± 0.95
|
11.7 ± 1.2
|
0.8
|
|
T. bilirubin (N < 1.5 mg/dl) median (IQR)
|
2.3 (1.1–5.1)
|
0.4 (0.2–0.8)
|
0.002*
|
|
D. bilirubin in median (IQR)
|
1.1 (0.5–3)
|
0.1 (0.05–0.2)
|
0.01*
|
|
ALT (N < 40 U/L) in median (IQR)
|
92 (32–178)
|
29 (20–45)
|
0.006*
|
|
AST (N < 60 U/L) in median (IQR)
|
55 (36–125)
|
37 (30–66)
|
0.1
|
|
GGT (N < 30 U/L) in median (IQR)
|
105 (36–114)
|
17 (11–64)
|
0.09
|
|
AP (N < 640 U/L) in median (IQR)
|
252 (180–533)
|
260 (192–371)
|
1.0
|
|
INR (N < 1.1) in mean ± SD
|
1.04 ± 0.04
|
1.1 ± 0.12
|
0.4
|
|
Cholesterol (N < 200 mg/dl) in mean ± SD
|
180 ± 47
|
134 ± 31
|
0.006*
|
|
HDL (mg/dl) in mean ± SD
|
38 ± 12
|
43 ± 9.5
|
0.3
|
|
LDL (mg/dl) in mean ± SD
|
120 ± 44
|
68 ± 29
|
0.002*
|
|
Triglyceride (N < 150 mg/dl) in median (IQR)
|
92 (62–115)
|
88 (62–119)
|
0.9
|
